Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 plus nivolumab in solid tumors with acquired resistance to immune checkpoint inhibitors
jRCT2033240023Phase 1Recruiting
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 and nivolumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), esophageal cancer and 1 more. Primary endpoints: Tolerability and safety and Efficacy: stable disease or better at Day 85. Started Jun 2024; status: recruiting.
02
Drugs
ADR-001nivolumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on jRCT2033240023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240023.